SNDX
insider transactionsSyndax Pharmaceuticals Inc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-73.5K
0 buy · 73.5K sell
Net value · 90d
-$1.3M
$0 in · $1.3M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
4
0 buy · 73.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 90d
-
Sell·S
Head of R&D, CMO · 10b5-1
$1.2M
65.5K sh · $18.07 avg · 2 lots
Own -52%
-
Sell·S
Chief Executive Officer
$130.0K
6.8K sh · $18.99
Own -1%
-
Sell·S
Goldan Keith A. KEY
Chief Financial Officer
$22.4K
1.2K sh · $18.99
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. 10b5-1 | Sell S | 65.5K2 lots | $1.2M |
| Jun 1, 2026 | Metzger Michael A KEY | Sell S | 6.8K | $130.0K |
| Jun 1, 2026 | Goldan Keith A. KEY | Sell S | 1.2K | $22.4K |
Buy Sell Non-market (grant · exercise · gift)
About SNDX insider trading
This page tracks insider transactions for Syndax Pharmaceuticals Inc (SNDX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.